By Chris Wack
Altimmune Inc. shares have been up 17% to $16.46 after the corporate mentioned it noticed optimistic leads to the interim evaluation of its Phase 1 trial of ALT-801, a weight-loss drug candidate geared toward treating non-alcoholic fatty liver illness.
Volume for the inventory was 18.5 million shares at 1:10 p.m. ET, in contrast with its 65-day common quantity of 1.1 million shares. The inventory traded as excessive as $19.46 earlier within the session.
ALT-801, an investigational GLP-1/glucagon twin receptor agonist, was administered to a bunch of wholesome chubby and overweight volunteers in Australia.
The biopharmaceutical firm mentioned the interim information confirmed a imply weight lack of 5.4% was achieved by the sixth week in contrast with a weight acquire of 0.9% within the placebo group, surpassing the pre-established remedy goal of two% weight reduction.
The firm mentioned ALT-801 was well-tolerated with out dose titration, with transient nausea charges of 14.3% on the 1.2 mg dose and 22.2% on the 1.8 mg dose, and no reviews of vomiting, diarrhea or constipation at both dose. All nausea occasions on the 1.8 mg dose have been delicate in severity.
The firm plans to broaden the enrollment standards and conduct a separate 12-week Phase 1b examine of diabetic and non-diabetic topics with non-alcoholic fatty liver illness within the U.S., which is anticipated to start within the third quarter of 2021.
The ALT-801 Phase 1 trial is progressing via greater dose cohorts, and the corporate plans to report the outcomes following 12 weeks of dosing within the third quarter of 2021. Based on these newest outcomes, Altimmune now plans to file a second investigational new drug software in weight problems within the third quarter to complement its ongoing NASH program.
Write to Chris Wack at [email protected]